FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140521560> ?p ?o ?g. }

• W2140521560 endingPage "472" @default.
• W2140521560 startingPage "464" @default.
• W2140521560 abstract "We developed and validated a new nonhuman primate model of laser-induced choroidal neovascularization (CNV) that addresses study design limitations prevalent in laser-induced CNV-based efficacy studies. Laser-induced Bruch’s membrane disruption triggers CNV and has been widely utilized in animals to model neovascular (“wet”) age-related macular degeneration (AMD). Despite widespread use of the approach, detailed assessment of experimental parameters and their influence on pathophysiological endpoints critical for disease modeling has been extremely limited and largely based on anecdotal observations. We evaluated laser power parameters and endpoint measures to optimize methods for CNV formation and quantification to facilitate drug efficacy screening in African green monkeys. Six laser spots of 350, 550, 750, 950 or 1500 mW laser power were positioned bilaterally 1.5 disc diameters from the fovea, within the macula. Fluorescein angiograms were collected 3–5 weeks later and scored by trained masked investigators using graded (I–IV) and densitometric methods. Histopathology assessments were also performed, including determination of CNV area. Test system sensitivity to angiogenesis inhibition was subsequently assessed by evaluating the effect of intravitreal bevacizumab (Avastin) pretreatment (one day prior to laser photocoagulation) on incidence of CNV. Grade III and grade IV lesions were considered clinically relevant, demonstrating early hyperfluorescence and late leakage within or beyond the lesion borders. By 4 weeks post-laser all treatment groups demonstrated evidence of grade III lesions with greatest incidence observed in lesions induced by 750 and 950 mW laser power (72.9% and 69.4% respectively). Grade IV lesions were confined to eyes receiving 550 mW laser power or higher, with highest incidence of grade IV lesions observed in eyes receiving 950 (19.4%) and 1500 mW (31%) laser spots, incidence peaking 4 weeks post-laser photocoagulation. Densitometric analyses of angiograms corroborated visual scoring. Bevacizumab completely abolished grade IV lesion development and significantly lowered lesion fluorescein signal intensity (P < 0.0001) and CNV area (P = 0.038) compared to vehicle-treated controls. Our studies demonstrate that laser power of 950–1500 mW and angiography analysis 4 weeks post-laser are optimal parameters to evaluate treatment effects on CNV induction following laser photocoagulation. Bevacizumab significantly attenuated CNV development, as determined by fluorescein angiography and histopathology assessments in this model, supporting the application of African green monkeys in preclinical modeling of CNV. Laser parameters and time points for therapeutic dosing and angiography endpoints are critical factors to the laser-induced CNV model and must be validated for robust assessment of efficacy. The newly optimized nonhuman primate model described will facilitate preclinical efficacy assessments of novel therapeutics for CNV." @default.
• W2140521560 created "2016-06-24" @default.
• W2140521560 creator A5001273604 @default.
• W2140521560 creator A5008172263 @default.
• W2140521560 creator A5009015684 @default.
• W2140521560 creator A5035373951 @default.
• W2140521560 creator A5065692542 @default.
• W2140521560 creator A5075700096 @default.
• W2140521560 creator A5081738635 @default.
• W2140521560 date "2011-06-01" @default.
• W2140521560 modified "2023-09-25" @default.
• W2140521560 title "Optimization of laser-induced choroidal neovascularization in African green monkeys" @default.
• W2140521560 cites W1965528611 @default.
• W2140521560 cites W1970874529 @default.
• W2140521560 cites W1971581751 @default.
• W2140521560 cites W1975107877 @default.
• W2140521560 cites W1983896293 @default.
• W2140521560 cites W1984187332 @default.
• W2140521560 cites W1992517723 @default.
• W2140521560 cites W1993501848 @default.
• W2140521560 cites W1997709600 @default.
• W2140521560 cites W2001343980 @default.
• W2140521560 cites W2006250353 @default.
• W2140521560 cites W2037160233 @default.
• W2140521560 cites W2052544334 @default.
• W2140521560 cites W2061563961 @default.
• W2140521560 cites W2065208295 @default.
• W2140521560 cites W2074816893 @default.
• W2140521560 cites W2079289507 @default.
• W2140521560 cites W2080143715 @default.
• W2140521560 cites W2090913210 @default.
• W2140521560 cites W2098155102 @default.
• W2140521560 cites W2114900908 @default.
• W2140521560 cites W2122761637 @default.
• W2140521560 cites W2124415048 @default.
• W2140521560 cites W2130645650 @default.
• W2140521560 doi "https://doi.org/10.1016/j.exer.2011.03.006" @default.
• W2140521560 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21414311" @default.
• W2140521560 hasPublicationYear "2011" @default.
• W2140521560 type Work @default.
• W2140521560 sameAs 2140521560 @default.
• W2140521560 citedByCount "34" @default.
• W2140521560 countsByYear W21405215602012 @default.
• W2140521560 countsByYear W21405215602013 @default.
• W2140521560 countsByYear W21405215602014 @default.
• W2140521560 countsByYear W21405215602015 @default.
• W2140521560 countsByYear W21405215602016 @default.
• W2140521560 countsByYear W21405215602017 @default.
• W2140521560 countsByYear W21405215602018 @default.
• W2140521560 countsByYear W21405215602019 @default.
• W2140521560 countsByYear W21405215602020 @default.
• W2140521560 countsByYear W21405215602021 @default.
• W2140521560 countsByYear W21405215602022 @default.
• W2140521560 countsByYear W21405215602023 @default.
• W2140521560 crossrefType "journal-article" @default.
• W2140521560 hasAuthorship W2140521560A5001273604 @default.
• W2140521560 hasAuthorship W2140521560A5008172263 @default.
• W2140521560 hasAuthorship W2140521560A5009015684 @default.
• W2140521560 hasAuthorship W2140521560A5035373951 @default.
• W2140521560 hasAuthorship W2140521560A5065692542 @default.
• W2140521560 hasAuthorship W2140521560A5075700096 @default.
• W2140521560 hasAuthorship W2140521560A5081738635 @default.
• W2140521560 hasConcept C118487528 @default.
• W2140521560 hasConcept C120665830 @default.
• W2140521560 hasConcept C121332964 @default.
• W2140521560 hasConcept C126322002 @default.
• W2140521560 hasConcept C141071460 @default.
• W2140521560 hasConcept C142724271 @default.
• W2140521560 hasConcept C203092338 @default.
• W2140521560 hasConcept C2776403814 @default.
• W2140521560 hasConcept C2776694085 @default.
• W2140521560 hasConcept C2777802072 @default.
• W2140521560 hasConcept C2778257484 @default.
• W2140521560 hasConcept C2778271429 @default.
• W2140521560 hasConcept C2780248432 @default.
• W2140521560 hasConcept C2780394083 @default.
• W2140521560 hasConcept C2781156865 @default.
• W2140521560 hasConcept C2781359195 @default.
• W2140521560 hasConcept C520434653 @default.
• W2140521560 hasConcept C535046627 @default.
• W2140521560 hasConcept C544855455 @default.
• W2140521560 hasConcept C71924100 @default.
• W2140521560 hasConceptScore W2140521560C118487528 @default.
• W2140521560 hasConceptScore W2140521560C120665830 @default.
• W2140521560 hasConceptScore W2140521560C121332964 @default.
• W2140521560 hasConceptScore W2140521560C126322002 @default.
• W2140521560 hasConceptScore W2140521560C141071460 @default.
• W2140521560 hasConceptScore W2140521560C142724271 @default.
• W2140521560 hasConceptScore W2140521560C203092338 @default.
• W2140521560 hasConceptScore W2140521560C2776403814 @default.
• W2140521560 hasConceptScore W2140521560C2776694085 @default.
• W2140521560 hasConceptScore W2140521560C2777802072 @default.
• W2140521560 hasConceptScore W2140521560C2778257484 @default.
• W2140521560 hasConceptScore W2140521560C2778271429 @default.
• W2140521560 hasConceptScore W2140521560C2780248432 @default.
• W2140521560 hasConceptScore W2140521560C2780394083 @default.
• W2140521560 hasConceptScore W2140521560C2781156865 @default.
• W2140521560 hasConceptScore W2140521560C2781359195 @default.

• next